Tema Etfs LLC Makes New $330,000 Investment in Immunocore Holdings plc (NASDAQ:IMCR)

Tema Etfs LLC acquired a new stake in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 11,194 shares of the company's stock, valued at approximately $330,000.

Other large investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. boosted its stake in shares of Immunocore by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock valued at $248,000 after acquiring an additional 960 shares during the last quarter. NEOS Investment Management LLC boosted its stake in shares of Immunocore by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock valued at $330,000 after acquiring an additional 1,102 shares during the last quarter. Virtus ETF Advisers LLC boosted its stake in shares of Immunocore by 39.0% during the fourth quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company's stock valued at $340,000 after acquiring an additional 3,238 shares during the last quarter. XTX Topco Ltd boosted its stake in shares of Immunocore by 22.2% during the fourth quarter. XTX Topco Ltd now owns 18,896 shares of the company's stock valued at $557,000 after acquiring an additional 3,437 shares during the last quarter. Finally, Barclays PLC boosted its stake in shares of Immunocore by 2,044.0% during the fourth quarter. Barclays PLC now owns 20,625 shares of the company's stock valued at $608,000 after acquiring an additional 19,663 shares during the last quarter. Institutional investors and hedge funds own 84.50% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on IMCR. Needham & Company LLC reaffirmed a "buy" rating and set a $71.00 price objective on shares of Immunocore in a research note on Thursday, April 10th. Oppenheimer raised their price target on Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. HC Wainwright reissued a "buy" rating and issued a $100.00 price target on shares of Immunocore in a research note on Wednesday, March 12th. Morgan Stanley reissued an "equal weight" rating and issued a $35.00 price target on shares of Immunocore in a research note on Friday, March 7th. Finally, Mizuho decreased their price target on Immunocore from $38.00 to $33.00 and set a "neutral" rating on the stock in a research note on Monday, April 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, Immunocore has a consensus rating of "Moderate Buy" and a consensus target price of $58.13.

Immunocore Trading Down 0.2%

Shares of Immunocore stock traded down $0.05 during trading hours on Friday, reaching $31.16. The stock had a trading volume of 98,828 shares, compared to its average volume of 388,676. The firm has a 50 day simple moving average of $29.01 and a two-hundred day simple moving average of $30.01. The firm has a market capitalization of $1.56 billion, a price-to-earnings ratio of -32.80 and a beta of 0.75. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. Immunocore Holdings plc has a 1 year low of $23.15 and a 1 year high of $49.05.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.45. The company had revenue of $125.13 million for the quarter, compared to the consensus estimate of $108.82 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The company's quarterly revenue was up 33.6% compared to the same quarter last year. During the same period last year, the business posted ($0.49) EPS. As a group, equities research analysts anticipate that Immunocore Holdings plc will post -0.94 earnings per share for the current year.

Insider Transactions at Immunocore

In other news, Director Bros. Advisors Lp Baker acquired 807,338 shares of the business's stock in a transaction dated Monday, March 17th. The shares were bought at an average cost of $29.72 per share, for a total transaction of $23,994,085.36. Following the acquisition, the director now directly owns 2,144,060 shares in the company, valued at $63,721,463.20. This trade represents a 60.40% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 10.40% of the company's stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.